Ranolazine for Angina in Hypertrophic Cardiomyopathy

Ranolazine is an antianginal and works by inhibiting late-sodium current (I(NaL)). However, its use is limited mostly to patients with coronary artery disease. However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy. Hereby, we discuss two cases where r...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Akhtar, Kim, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925191/
https://www.ncbi.nlm.nih.gov/pubmed/29850265
http://dx.doi.org/10.1155/2018/5142572
_version_ 1783318667455365120
author Amin, Akhtar
Kim, Bernard
author_facet Amin, Akhtar
Kim, Bernard
author_sort Amin, Akhtar
collection PubMed
description Ranolazine is an antianginal and works by inhibiting late-sodium current (I(NaL)). However, its use is limited mostly to patients with coronary artery disease. However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy. Hereby, we discuss two cases where ranolazine led to improvement in angina refractory to beta-blockers. In conclusion, ranolazine can be considered as a potential antianginal drug in patients with hypertrophic cardiomyopathy refractory to beta-blockers.
format Online
Article
Text
id pubmed-5925191
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59251912018-05-30 Ranolazine for Angina in Hypertrophic Cardiomyopathy Amin, Akhtar Kim, Bernard Case Rep Cardiol Case Report Ranolazine is an antianginal and works by inhibiting late-sodium current (I(NaL)). However, its use is limited mostly to patients with coronary artery disease. However, literature has shown its potential benefit in relieving angina in hypertrophic cardiomyopathy. Hereby, we discuss two cases where ranolazine led to improvement in angina refractory to beta-blockers. In conclusion, ranolazine can be considered as a potential antianginal drug in patients with hypertrophic cardiomyopathy refractory to beta-blockers. Hindawi 2018-04-15 /pmc/articles/PMC5925191/ /pubmed/29850265 http://dx.doi.org/10.1155/2018/5142572 Text en Copyright © 2018 Akhtar Amin and Bernard Kim. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Amin, Akhtar
Kim, Bernard
Ranolazine for Angina in Hypertrophic Cardiomyopathy
title Ranolazine for Angina in Hypertrophic Cardiomyopathy
title_full Ranolazine for Angina in Hypertrophic Cardiomyopathy
title_fullStr Ranolazine for Angina in Hypertrophic Cardiomyopathy
title_full_unstemmed Ranolazine for Angina in Hypertrophic Cardiomyopathy
title_short Ranolazine for Angina in Hypertrophic Cardiomyopathy
title_sort ranolazine for angina in hypertrophic cardiomyopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925191/
https://www.ncbi.nlm.nih.gov/pubmed/29850265
http://dx.doi.org/10.1155/2018/5142572
work_keys_str_mv AT aminakhtar ranolazineforanginainhypertrophiccardiomyopathy
AT kimbernard ranolazineforanginainhypertrophiccardiomyopathy

Ejemplares similares